Click here to see a list of our past events.
Center for Technology Licensing (CTL) at Weill Cornell Medicine Office Hours are open to all who wish to gain more information about the advancement of their patent filings and to discuss their technology venture project in a one-on-one meeting with a business development and licensing professional. The October office hours will be hosted by Brian Kelly, Ph.D., CLP, director of business development and licensing.
Brian manages a portfolio of inventions focusing on oncology, gene therapy, metabolic diseases, the microbiome and endocrine disorders. Prior to joining CTL at Weill Cornell, he served as director of intellectual property for New York University’s tech transfer office. He has also held positions at the University of Minnesota as a licensing associate, Heide, Hyde & O’Donnell as an associate European patent attorney and Smith, Kline & French as a research chemist.
Email enterpriseinnovation@med.cornell.edu for your 30-minute private session.
AI Day brings together a Nobel laureate designing proteins from scratch and the scientist who leads drug discovery and development research at Anthropic.
David Baker, director of the Institute for Protein Design at the University of Washington, returns to talk about the progress and challenges as de novo proteins move from the lab toward becoming drugs, and how that could lead to dramatically different types of medicines. Then, in a livestreamed fireside chat, Anthropic's Nathan Frey will discuss the company's latest advances in the life sciences and its vision for the AI future of the drug industry.
Could your innovative research change the world?
Participate in a free, month-long I-Corps Regional Course to receive expert guidance as you evaluate the market potential of your deep technology innovation. You’ll gain a deeper understanding of your field and learn valuable professional skills in the process.
The following virtual courses are open to innovators in all STEM fields:
- July 27 – August 26: For startup/incubator teams. Apply by July 8.
- September 4 – October 7: Apply by August 19.
- October 12 – November 12: Apply by September 16.
- October 19 – November 18: Apply by September 23.
- October 19 – November 18: For startup/incubator teams. Apply by September 23.
- November 11 – December 16: Apply by October 14.
Applications will be reviewed on a rolling basis. Please contact icorps@cornell.edu for any questions.
Are you a STEM researcher interested in making an impact with your technology innovation? The National Science Foundation’s I-Corps program can provide you with professional training, mentoring and up to $50,000 in funding for customer discovery.
Hosted by the Interior Northeast I-Corps Hub (IN I-Corps), the virtual NSF I-Corps Information Session on Tuesday, October 13 (12:00 – 1:00 p.m. ET) is designed for busy graduate students, postdocs, and faculty interested in learning more about I-Corps regional and national programming. NSF I-Corps instructor Greg Ray and program alum Zach Spears will be in attendance to share their experience and answer questions.
The NSF created I-Corps (Innovation Corps) to bridge the gap between fundamental research discoveries in science and engineering and the commercialization of technologies, products and processes with the potential to benefit society.
You are invited to join the Weill Cornell Medicine community for Revolutionizing Healthcare with AI-Powered Devices, a showcase of digital health innovations and technologies.
This event is part of #AIWeekNY, a community-led festival organized by Pulse NYC that celebrates innovation across the AI ecosystem.
The following innovators and their AI-enabled technologies will be featured:
EmulatRx
An agentic AI platform that uses real-world patient data to support clinical trial design. Presented by Weishen Pan, PhD, Research Associate, Department of Population Health Sciences, Weill Cornell Medicine
WAV AI
An AI-based tool that analyzes sounds to detect fistula stenosis. Presented by Bobak Mosadegh, PhD, Associate Professor of Biomedical Engineering in Radiology and Director, Dalio Institute of Cardiovascular Imaging, Weill Cornell Medicine
Postpartum Depression Risk Prediction
An Epic-integrated clinical decision support tool that analyzes electronic health record data to identify pregnant patients at elevated risk for postpartum depression. Presented by Yiye Zhang, PhD, MS, Associate Professor of Population Health Sciences, Weill Cornell Medicine
Corneal Confocal Microscopy for Neurodegenerative Disease Detection
A noninvasive approach that uses corneal confocal microscopy to detect changes in the cornea’s small nerve fibers. Quantitative imaging and predictive analysis may offer an accessible biomarker for detecting and monitoring neurodegeneration. Presented by Rayaz A. Malik, MBChB, PhD, FRCP, Professor of Medicine, Weill Cornell Medicine–Qatar
Join Johnson & Johnson virtually for the live broadcast of their flagship data science event in Basel (Switzerland) on what it will take for AI to move from hype to embedded impact in pharma R&D. Together with leaders from Johnson & Johnson and the European innovation ecosystem, we will explore which Digital, Data Science & AI capabilities are likely to create durable value in drug discovery and development, including frontier models for biology, digital health and AI biomarkers, GenAI for scientific reasoning, and agentic technologies that can support R&D workflows.
The event is designed for startups, scale-ups, academic innovators, investors and ecosystem partners interested in building AI capabilities that are differentiated, scalable and relevant to real R&D needs.
The oncology innovation landscape has become increasingly competitive, with capital, strategic attention and acquisition interest concentrated around companies that can show clear differentiation early. For emerging oncology companies, scientific novelty alone is no longer enough. Investors and potential buyers are looking for focused strategies, credible development paths, and a clear view of where a company can create value in a crowded market.
J&J invites you to an event focused on how oncology startups can position themselves for investment, partnership, and potential acquisition in today’s market. The discussion will explore what different types of investors and acquirers are looking for, how expectations are evolving around patient selection and clinical trial design, and how companies can make strategic choices earlier in development that strengthen their future options. The program will also examine how buyer expectations differ across the oncology ecosystem.
The program is tailored to oncology startups, academic innovators, investors, TTOs, incubators, and ecosystem partners interested in how promising oncology science can be translated into companies that are strategically focused, commercially credible, and attractive to future partners or buyers.
Register here to attend virtually.
You are invited to join us on Thursday, October 1, from 11:00am–12:00pm, when CDR Michael Banyas, USPHS, M.P.A., M.A., Health Specialist at the National Institute on Minority Health and Health Disparities (NIMHD), will visit Weill Cornell Medicine’s campus. NIMHD has a special interest in women’s health and solutions to address health disparities.
The session will take place at BioVenture eLab, a part of Weill Cornell Medicine Enterprise Innovation, and will also be available via Zoom.
During the session, CDR Banyas will provide an overview of NIMHD programs and funding opportunities, including:
- New and current funding programs
- Reauthorization highlights
- Application tips and suggestions
- Commercialization resources for applicants and awardees
This will be a great opportunity for WCM faculty, researchers, and members of the broader NYC scientific community to learn more about NIMHD resources.
Please register here.
If you have any questions, please reach out to Loren Busby, Director, BioVenture eLab, at lob4002@med.cornell.edu.
Center for Technology Licensing (CTL) at Weill Cornell Medicine Office Hours are open to all who wish to get an answer to their intellectual property questions and gain more information about the advancement of their IP filings with a one-on-one meeting.
The Tuesday, September 22, office hours will be hosted virtually by Eric Bryant, Intellectual Property Officer, Biomedical Sciences.
Eric holds a Master of Science in Biomedical Engineering from New York University, a Juris Doctor from New York Law School, and is a registered patent attorney. He works with the Weill Cornell office to execute on intellectual property strategy, review submitted invention disclosures, and manage domestic and foreign patent filings and patent prosecution. Eric’s expertise encompasses a variety of technologies including, but not limited to, diagnostics tools and methods, pharmaceuticals, controlled release therapeutic devices, respiratory devices, surgical tools, biological technologies and nanotechnology.
Register here for your 30-minute private session.
Center for Technology Licensing (CTL) at Weill Cornell Medicine Office Hours are open to all who wish to gain more information about the advancement of their patent filings and to discuss their technology venture project with a one-on-one meeting with a Weill Cornell business development and licensing professional.
This month's office hours will be hosted by Louise Sarup, Ph.D., associate director, business development and licensing. Louise manages a portfolio of medical technologies focusing on imaging, platform technologies and algorithms. She is a seasoned professional with years of experience in licensing and commercialization and is eager to answer your questions and provide valuable insights.
Prior to joining the Center for Technology Licensing, Louise was based in Singapore where she was head of business development and licensing for D3 (now EDDC), a drug discovery and development group based at A*STAR. Some of her previous roles include corporate development manager at S*BIO Pte Ltd. (Singapore), an oncology-focused biotech, vice president of business development at Paramount Biosciences (London), where she was responsible for in-licensing drug development assets and director (licensing) at Cytiva, a global life science company. Louise has also worked for leading life science and health care communication agencies and UCL Business, the commercialization company of University College London.
Register here for your 30-minute private session.
